Last reviewed · How we verify
Intravitreal topotecan
Topoisomerase I inhibitor
Topoisomerase I inhibitor Used for Retinoblastoma, Malignant glioma.
At a glance
| Generic name | Intravitreal topotecan |
|---|---|
| Also known as | Topotecan |
| Sponsor | Unity Health Toronto |
| Drug class | Topoisomerase inhibitor |
| Target | Topoisomerase I |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Topotecan works by inhibiting topoisomerase I, an enzyme involved in DNA replication and transcription. This leads to DNA damage and ultimately cell death in rapidly dividing cancer cells.
Approved indications
- Retinoblastoma
- Malignant glioma
Common side effects
- Vision disorder
- Cytopenia
Key clinical trials
- The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy (PHASE1)
- Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome (PHASE2, PHASE3)
- High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed (EARLY_PHASE1)
- Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment (PHASE2)
- Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy (PHASE2)
- A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |